IL6 and irritable bowel syndrome: Both taVNS and needle-based VNS decrease TNF-α and IL-6 levels in IBS patients (Shi et al. 2021) and in a rodent model of TNBS-induced colitis (Jin et al. 2017), suggesting that the effect of VNS is mediated through the inhibition of pro-inflammatory cytokines.